Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (161-170 of 272) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|June 12, 2014
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritisPhilip J Mease, Mark C Genovese, Maria W Greenwald, et al.
RMD Open|May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extensionVictoria Navarro-Compán, Uta Kiltz, Philip J Mease, et al.
Rheumatology (Oxford, England)|October 20, 2021
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibitionIain B McInnes, Zoltán Szekanecz, Dennis McGonagle, et al.
Rheumatology and Therapy|October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 StudyPhilip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
Arthritis Care & Research|February 6, 2014
Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary American College of Rheumatology criteria and the development of alternative criteriaRobert M Bennett, Ronald Friend, Dawn Marcus, et al.
Rheumatology and Therapy|October 7, 2021
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing SpondylitisIrene van der Horst-Bruinsma, Corinne Miceli-Richard, Juergen Braun, et al.
ACR Open Rheumatology|June 23, 2022
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd StudyPhilip C Robinson, Walter P Maksymowych, Lianne S Gensler, et al.
Arthritis Research & Therapy|September 18, 2023
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyXenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
Pharmacoepidemiology and Drug Safety|August 25, 2025
Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing VariationsMaureen Dubreuil, Jessica A Walsh, Atul Deodhar, et al.
Clinical Rheumatology|September 14, 2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trialJohn D Reveille, Mark C Hwang, Abhijeet Danve, et al.
Pageof 28

Showing results (161-170 of 272) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|June 12, 2014
Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritisPhilip J Mease, Mark C Genovese, Maria W Greenwald, et al.
RMD Open|May 13, 2026
Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extensionVictoria Navarro-Compán, Uta Kiltz, Philip J Mease, et al.
Rheumatology (Oxford, England)|October 20, 2021
A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibitionIain B McInnes, Zoltán Szekanecz, Dennis McGonagle, et al.
Rheumatology and Therapy|October 11, 2023
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 StudyPhilip J Mease, Dafna D Gladman, Denis Poddubnyy, et al.
Arthritis Care & Research|February 6, 2014
Criteria for the diagnosis of fibromyalgia: validation of the modified 2010 preliminary American College of Rheumatology criteria and the development of alternative criteriaRobert M Bennett, Ronald Friend, Dawn Marcus, et al.
Rheumatology and Therapy|October 7, 2021
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing SpondylitisIrene van der Horst-Bruinsma, Corinne Miceli-Richard, Juergen Braun, et al.
ACR Open Rheumatology|June 23, 2022
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd StudyPhilip C Robinson, Walter P Maksymowych, Lianne S Gensler, et al.
Arthritis Research & Therapy|September 18, 2023
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III studyXenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, et al.
Pharmacoepidemiology and Drug Safety|August 25, 2025
Real-World Use of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing VariationsMaureen Dubreuil, Jessica A Walsh, Atul Deodhar, et al.
Clinical Rheumatology|September 14, 2020
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trialJohn D Reveille, Mark C Hwang, Abhijeet Danve, et al.
Pageof 28